A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria

Trieu Nguyen Trung; Bo Tan; Dang Van Phuc; Jian-ping Song

doi:10.1007/s11655-009-0189-6

Your Location：

Home >

Browse articles >

A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria

Updated：2021-08-27

- A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria
- Chinese Journal of Integrative Medicine Vol. 15, Issue 3, Pages: 189-192(2009)
- Affiliations：
  
  1. Institute of Malariology, Parasitology and Entomology-Qui Nhon, Ministry of Health, Qui Nhon,Vietnam
  2. Research Center for Qinghao (Artemisia annual L.), Guangzhou University of Chinese Medicine,Guangzhou,China
- Author bio：
- Funds：
  
  Supported by Science and Technology Research Projects of Guangdong Province (No. 2005A30101009)
- DOI：10.1007/s11655-009-0189-6
  CLC：
- Published：2009，
  
  Published Online：2 July 2009，
Scan for full text
Trung, T.N., Tan, B., Van Phuc, D. et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria., Chin. J. Integr. Med. 15, 189–192 (2009). https://doi.org/10.1007/s11655-009-0189-6

Trieu Nguyen Trung, Bo Tan, Dang Van Phuc, et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. [J]. Chinese Journal of Integrative Medicine 15(3):189-192(2009)
Trung, T.N., Tan, B., Van Phuc, D. et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria., Chin. J. Integr. Med. 15, 189–192 (2009). https://doi.org/10.1007/s11655-009-0189-6 DOI：

Trieu Nguyen Trung, Bo Tan, Dang Van Phuc, et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. [J]. Chinese Journal of Integrative Medicine 15(3):189-192(2009) DOI： 10.1007/s11655-009-0189-6.

摘要

The study aimed to evaluate and compare the efficacy and safety of dihydroartemisinin-piperaquine phosphate (Artekin) and artemisinin-piperaquine (Artequick) in the treatment of uncomplicated falciparum malaria. A total of 103 uncomplicated falciparum malaria patients were enrolled and randomly assigned to two groups: 52 cases in the Artequick group

and 51 cases in the Artekin group. The patients in the Artequick group were administered with Artequick

twice in 24 h

whereas the patients in the Artekin group were given Artekin 4 times in 2 days. The mean parasite clearance time

mean fever clearance time

28-day cure rate and parasite recrudescence rates of the two groups were then compared. The mean parasite clearance time and the mean fever clearance time were 43.2±13.9 h and 24.7±9.9 h

in the Artequick group

and 36.5±17.1 h and 22.7±11.2 h

in the Artekin group. In both groups the 28-day cure rate was 100%

and the parasite recrudescence rate was 0. Both medicines had high cure rates

low recrudescence rates

and no serious adverse reactions. The administration of Artequick

however

was more convenient and lower incidence of gastrointestinal side effects than that of Artekin

so as to increase the efficacy in the malaria population.

Abstract

and 51 cases in the Artekin group. The patients in the Artequick group were administered with Artequick

twice in 24 h

whereas the patients in the Artekin group were given Artekin 4 times in 2 days. The mean parasite clearance time

mean fever clearance time

28-day cure rate and parasite recrudescence rates of the two groups were then compared. The mean parasite clearance time and the mean fever clearance time were 43.2±13.9 h and 24.7±9.9 h

in the Artequick group

and 36.5±17.1 h and 22.7±11.2 h

in the Artekin group. In both groups the 28-day cure rate was 100%

and the parasite recrudescence rate was 0. Both medicines had high cure rates

low recrudescence rates

and no serious adverse reactions. The administration of Artequick

however

was more convenient and lower incidence of gastrointestinal side effects than that of Artekin

so as to increase the efficacy in the malaria population.

关键词

plasmodium falciparumMalariaArtemisininpiperaquineantimalarialsrandomized controlled trial

Keywords

plasmodium falciparumMalariaArtemisininpiperaquineantimalarialsrandomized controlled trial

references

Jose A. Najera, Joahim Hempel. The burden of malaria, CTD/MAL/96.10. http://www.rbm.who.int/cmc_upload/0/000/009/511/burden_najera.pdf

WHO. World malaria report. Geneva: World Health Organization; 2005. http://www.unicef.org/media/files/MalariaFactSheet.pdf

WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006. http://whqlibdoc.who.int/publications/2006/9241546948_eng.pdf

WHO. Assessment and monitoring of Antimalarial drug efficacy for the treatment of uncompcicated falciparum malaria. Geneva: World Health Organization; 2003. http://www.who.int/malaria/docs/ProtocolWHO.pdf

Song JP, Socheat D, Seila S, Tharith T, Satim S, Yuthease S, et al. Clinical observation of dihydroartemisinin-piperaquine phosphate in treatment of uncomplicated falciparum malaria. Natl Med J Chin (Chin) 2003;83: 1099–1100.

Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006;100:1105–1111.

Tangpukdee N, Krudsood S, Thanachartwet W, Chalermrut K, Pengruksa C, Srivilairit S, et al. An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2005;36:1085–1091.

Song JP, Fu LC, Tan B, Li GQ. Randomized controlled trial of dihydroartemisinin piperaquine phosphate tablets in treatment of uncomplicated falciparum malaria. Chin J New Drugs (Chin) 2004;11: 783–785.

Chen L, Qu FY, Zhou YC. Field observation on the antimalarial piperaquine. Chin J Med (Chin) 1982; 95:281–286.

Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, et al. Dihydroartemisinin-piperaquine against multidrug-resistant plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004;363:18–22.

FULL TEXT LINK

More>

Views

352

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line

Endorsement of CONSORT by Chinese medical journals: A survey of “instruction to authors”

A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism

Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials

Efficacy of Gastrosis No.1 compound on functional dyspepsia of spleen and stomach deficiency-cold syndrome: A multi-center, double-blind, placebo-controlled clinical trial

Related Author

No data

Related Institution

Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran

Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran

Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine

First Hospital Affiliated to Tianjin University of Traditional Chinese Medicine

Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰